Valproic AcId for Traumatic BRAin INjury Trial

The long-term goal of the clinical trial is to develop effective, safe, and easily administered life-saving treatments for patients with moderate to severe traumatic brain injury (TBI). Patients with moderate to severe TBI will randomly receive either: 1. Standard of care treatment and normal saline 2. Standard of care treatment and one dose of valproic acid (VPA) at a lower dose or a higher dose

NCT Number	NCT07166393
Lead Sponsor	Northwestern University Collaborators: United States Department of Defense
Conditions	Moderate Traumatic Brain Injury (TBI), Severe Traumatic Brain Injury
Enrollment	432 participants
Start Date	2027-05
Primary Completion	2031-05 (estimated)
Study Completion	2031-12 (estimated)
Updated on ClinicalTrials.gov	2026-08-13